{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ciampricotti M"],"funding":["NCI","NCI NIH HHS","American Cancer Society Research Scholar Grant","NIGMS NIH HHS"],"pagination":["3214-3229"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8810895"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(12)"],"pubmed_abstract":["Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in SCLC, most notably an in-frame gene fusion between RLF and MYCL found in up to 7% of the predominant ASCL1-expressing subtype. To explore the role of this fusion in oncogenesis and tumor progression, we used CRISPR/Cas9 somatic editing to generate a Rlf-Mycl-driven mouse model of SCLC. RLF-MYCL fusion accelerated transformation and proliferation of murine SCLC and increased metastatic dissemination and the diversity of metastatic sites. Tumors from the RLF-MYCL genetically engineered mouse model displayed gene expression similarities with human RLF-MY"],"journal":["Cancer discovery"],"pubmed_title":["Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer."],"pmcid":["PMC8810895"],"funding_grant_id":["U24 CA213274","U01 CA231844","P30 CA008748","R01CA227649","R37 CA222504","T32 GM007753","R01 CA227649","R01 CA197936","RSG-17-200-01-TBE","R37CA222504"],"pubmed_authors":["Allaj V","Papagiannakopoulos T","Richards AL","Quintanal-Villalonga A","Caeser R","Kombak FE","Spainhower KB","Ventura A","Donoghue MTA","Manoj P","Maddalo D","Sanchez-Rivera FJ","Zavitsanou AM","Costa EA","Poirier JT","Ciampricotti M","Jacks T","Karatza A","Sen T","Rideout WM","Oliver TG","Jaspers JE","Karakousi T","Rudin CM","Akama-Garren EH"],"additional_accession":[]},"is_claimable":false,"name":"Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.","description":"Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in SCLC, most notably an in-frame gene fusion between RLF and MYCL found in up to 7% of the predominant ASCL1-expressing subtype. To explore the role of this fusion in oncogenesis and tumor progression, we used CRISPR/Cas9 somatic editing to generate a Rlf-Mycl-driven mouse model of SCLC. RLF-MYCL fusion accelerated transformation and proliferation of murine SCLC and increased metastatic dissemination and the diversity of metastatic sites. Tumors from the RLF-MYCL genetically engineered mouse model displayed gene expression similarities with human RLF-MY","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-05-09T03:53:09.582Z","creation":"2024-11-15T12:38:32.047Z"},"accession":"S-EPMC8810895","cross_references":{"pubmed":["34344693"],"doi":["10.1158/2159-8290.cd-21-0441","10.1158/2159-8290.CD-21-0441"]}}